iBio, Inc. (IBIO)
NASDAQ: IBIO · Real-Time Price · USD
0.7903
+0.0422 (5.64%)
Nov 18, 2026, 12:47 PM EST - Market open
iBio, Inc. Revenue
iBio, Inc. had revenue of $1.08M in the quarter ending September 30, 2026, with 975.00% growth. This brings the company's total for the last twelve months to $1.08M, up 115.00% year-over-year. In the fiscal year ending June 30, 2026, iBio, Inc. had annual revenue of $100.00K, down -75.00%. That makes iBio, Inc. the 43,519th largest company in the world by revenue and 6,066th in the United States.
Revenue (ttm)
$1.08M
Revenue Growth
+115.00%
P/S Ratio
44.75
Revenue / Employee
$46,739
Employees
23
Market Cap
50.82M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 100.00K | -300.00K | -75.00% |
| Jun 30, 2025 | 400.00K | 175.00K | 77.78% |
| Jun 30, 2024 | 225.00K | - | - |
| Jun 30, 2023 | - | - | - |
| Jun 30, 2022 | 1.88M | -487.00K | -20.54% |
| Jun 30, 2021 | 2.37M | 733.00K | 44.75% |
| Jun 30, 2020 | 1.64M | -380.00K | -18.83% |
| Jun 30, 2019 | 2.02M | 1.57M | 354.50% |
| Jun 30, 2018 | 444.00K | 50.00K | 12.69% |
| Jun 30, 2017 | 394.00K | -554.00K | -58.44% |
| Jun 30, 2016 | 948.00K | -903.00K | -48.78% |
| Jun 30, 2015 | 1.85M | 1.65M | 802.93% |
| Jun 30, 2014 | 205.00K | -802.00K | -79.64% |
| Jun 30, 2013 | 1.01M | -270.00K | -21.14% |
| Jun 30, 2012 | 1.28M | 756.92K | 145.54% |
| Jun 30, 2011 | 520.08K | - | - |
| Jun 30, 2010 | - | - | - |
| Jun 30, 2009 | 1.18M | 189.55K | 19.20% |
| Jun 30, 2008 | 987.06K | 90.79K | 10.13% |
| Jun 30, 2007 | 896.27K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Heron Therapeutics | 148.22M |
| Spero Therapeutics | 41.56M |
| Verrica Pharmaceuticals | 22.89M |
| Werewolf Therapeutics | 21.00M |
| Clene | 238.00K |
IBIO News
- 1 day ago - iBio reports extended preclinical data from NHP study of IBIO-610 - TheFly
- 1 day ago - iBio Announces New Preclinical Data Across Obesity and Cardiometabolic Portfolio at Multiple Scientific Conferences - GlobeNewsWire
- 7 days ago - iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 days ago - iBio, Inc. Earnings release: Q1 2027 - Filings
- 7 days ago - iBio, Inc. Quarterly report: Q1 2027 - Filings
- 8 days ago - iBio, Inc. Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 8 days ago - iBio, Inc. Slides: Corporate presentation - Filings
- 15 days ago - iBio to Participate in Upcoming Investor Conferences - GlobeNewsWire